185315-48-4

Basic information

• Product Name: (4-Bromo-2-chlorophenyl)methanol
• Synonyms: (4-Bromo-2-chlorophenyl)methanol;4-Bromo-2-chlorobenzyl alcohol;4-BroMo-2-chloro-benzeneMethanol;BENZENEMETHANOL, 4-BROMO-2-CHLORO;4-Bromo-2-chlorobenzyl alchol
• CAS NO: 185315-48-4
• Molecular Formula: C₇H₆BrClO
• Molecular Weight: 221.47894
• Mol File: 185315-48-4.mol
• Article Data: 30

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: (4-Bromo-2-chlorophenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Bromo-2-chlorophenyl)methanol(185315-48-4)
• EPA Substance Registry System: (4-Bromo-2-chlorophenyl)methanol(185315-48-4)

Safety Data

• Hazardous Substances Data: 185315-48-4(Hazardous Substances Data)

Usage

General Description

(4-Bromo-2-chlorophenyl)methanol, also known as 2-(4-Bromo-2-chlorophenyl)ethanol, is an organic compound with the chemical formula C8H7BrClO. It is a white to off-white solid that is commonly used in the synthesis of various pharmaceuticals and agrochemicals, as well as in the production of fragrances and flavors. (4-Bromo-2-chlorophenyl)methanol is also used as a chiral auxiliary in organic synthesis, particularly in the preparation of chiral drugs. It is a versatile building block in organic chemistry, with potential applications in the development of new molecules and materials. Additionally, (4-Bromo-2-chlorophenyl)methanol has been studied for its potential antimicrobial and antifungal properties, making it a valuable compound for the pharmaceutical and agricultural industries.

Upstream product

• 89794-02-5 4-bromo-2-chlorotoluene 
• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 25118-59-6 4-bromo-3-chlorobenzoic acid 
• 158435-41-7 4-bromo-2-chlorobenzaldehyde 
• 185312-82-7 4-bromo-2-chlorobenzoic acid methyl ester 

Downstream Products

• 158435-41-7 4-bromo-2-chlorobenzaldehyde 
• 89720-77-4 4-bromo-1-bromomethyl-2-chlorobenzene 

Relevant articles and documents

Triazole derivative as well as preparation method and application thereof

The invention relates to a triazole derivative as well as a preparation method and application thereof, which belong to the technical field of organic synthetic drugs. The structure of the triazole derivative is shown as a formula I. In the formula I, R1 and R2 are H, Cl, Br,-CF3,-CH(CH3)2 or -OCH3, and R1 and R2 are not H at the same time. R3 is -CH2 or -COCH2; X and Y are N or C, X and Y are not C at the same time, and X and Y are not N at the same time. The triazole derivative disclosed by the invention has a certain inhibition effect on germs of various crop diseases. Small toxic andside effects on plants are achieved. The preparation method of the triazole derivative is simple.

Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation

Transthyretin (TTR) is a homotetrameric protein. Its dissociation into monomers leads to the formation of fibrils that underlie human amyloidogenic diseases. The binding of small molecules to the thyroxin-binding sites in TTR stabilizes the homotetramer and attenuates TTR amyloidosis. Herein, we report on boronic acid-substituted stilbenes that limit TTR amyloidosis in vitro. Assays of affinity for TTR and inhibition of its tendency to form fibrils were coupled with X-ray crystallographic analysis of nine TTR·ligand complexes. The ensuing structure-function data led to a symmetrical diboronic acid that forms a boronic ester reversibly with serine 117. This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. These findings establish a new modality for covalent inhibition of fibril formation and illuminate a path for future optimization.

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.